EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Rewiring cancer metabolism: oncogenic signaling pathways and targeted therapeutics

Siying Lyu, Nina Gildor, Qing Zhang, Chengheng Liao

Science China Life Sciences · 2025-11 · 68 (11) · 3281-3302

DOI: 10.1007/s11427-025-2979-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Science China Life Sciences, online erschienen am 25.07.2025. Verfasst von Siying Lyu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. Hauptthemen laut MEDLINE: Neoplasms, Signal Transduction. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 289 Literaturangaben. Gefördert von: NCRR NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic reprogramming is a hallmark of cancer, playing a critical role in tumorigenesis by supporting cancer cell survival, proliferation, metastasis, and immune evasion. Oncogenic signaling pathways regulate key metabolic processes by orchestrating gene expression and enhancing metabolic enzyme activity, ensuring cancer cells meet their bioenergetic and biosynthetic demands. Here, we highlight the roles of major oncogenic metabolic signaling pathways, including phosphoinositide 3-kinase (PI3K)/AKT, Myc, p53, and hypoxia-inducible factor (HIF), in driving metabolic rewiring. We provide a conceptual framework to understand why metabolic reprogramming occurs in tumor cells, how metabolic alterations contribute to tumorigenesis, metastasis, and immune evasion, and the therapeutic implications of targeting these metabolic vulnerabilities in cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsSignal TransductionHumansPhosphatidylinositol 3-KinasesAnimalsCarcinogenesisMolecular Targeted TherapyProto-Oncogene Proteins c-aktTumor Suppressor Protein p53

Stichwörter der Autor:innen

cancer metabolismcell proliferationimmune evasionmetastasisoncogenic signaling pathwaystarget therapy

Substanzen

Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
  • Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. Qing.Zhang@UTSouthwestern.edu.
  • Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. Qing.Zhang@UTSouthwestern.edu.
  • Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. Chengheng.Liao@UTSouthwestern.edu.

Förderung

  • NCRR NIH HHS
  • NCI NIH HHS

Zitieren

APA

Lyu, S., Gildor, N., Zhang, Q., & Liao, C. (2025). Rewiring cancer metabolism: oncogenic signaling pathways and targeted therapeutics. Science China Life Sciences, 68(11), 3281-3302. https://doi.org/10.1007/s11427-025-2979-3

Vancouver

Lyu S, Gildor N, Zhang Q, Liao C. Rewiring cancer metabolism: oncogenic signaling pathways and targeted therapeutics. Science China Life Sciences. 2025;68(11):3281-3302. doi:10.1007/s11427-025-2979-3

BibTeX
@article{Lyu2025,
  author = {Lyu, Siying and Gildor, Nina and Zhang, Qing and Liao, Chengheng},
  title = {Rewiring cancer metabolism: oncogenic signaling pathways and targeted therapeutics},
  journal = {Science China Life Sciences},
  year = {2025},
  volume = {68},
  number = {11},
  pages = {3281--3302},
  doi = {10.1007/s11427-025-2979-3}
}
Kostenlos starten →